Remimazolam: An Updated Review of a New Sedative and Anaesthetic
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Remimazolam (CNS7056) is a novel benzodiazepine for intravenous sedation; it has an ultra-short duration of action and was recently approved for use in procedural sedation and general anaesthesia. It acts on γ-aminobutyric acid type A receptors and is rapidly converted into an inactive metabolite by tissue esterase enzymes. Remimazolam has been successfully used in endoscopic inspection or surgery and general anaesthesia induction and maintenance with fast and predictable onset and recovery times, high procedure success rates, and minor respiratory and hemodynamic fluctuations and without serious drug-related adverse reactions. If needed, the effects of remimazolam can be reversed by flumazenil, which allows prompt termination of sedation. Although remimazolam has great potential for sedation in patients admitted to intensive care units, future studies are needed to evaluate its efficacy and safety in patients requiring sedation for a long period, and numerous studies are warranted to explore the optimal dose in different application scenarios. The review aimed to provide an introduction to the process of remimazolam synthesis and its current clinical uses and future clinical developments.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Doi, M., Morita, K., Takeda, J., Sakamoto, A., Yamakage, M., & Suzuki, T. (2020) · Journal of Anesthesia · doi:10.1007/s00540-020-02788-6 · Cited by 484 · cited 5×
“Remimazolam decreased the incidence of hypotension and low SpO2.(49,52) The safety data of ASA class III patients were in line with the corresponding data from patients with ASA class I and II.”
BackgroundResultInfluentialKilpatrick (2007) · doi:10.1097/01.anes.0000267503.85085.c0 · Cited by 381
Chen, S., Yuan, T., Zhang, J., Bai, H., Tian, M., Pan, C., Bao, H., Jin, X., Ji, F., Zhong, T., et al. (2021) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.15188 · Cited by 270
Remimazolam: non-clinical and clinical profile of a new sedative/anesthetic agent
Kilpatrick, G. J. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.690875 · Cited by 262 · cited 4×
“It was also approved for compassionate use in intensive care unit (ICU) sedation in Belgium in August 2020.(15) (Figure 1).”
BackgroundInfluentialDoi, M., Hirata, N., Suzuki, T., Morisaki, H., Morimatsu, H., & Sakamoto, A. (2020) · Journal of Anesthesia · doi:10.1007/s00540-020-02776-w · Cited by 242 · cited 5×
“49,52 The safety data of ASA class III patients were in line with the corresponding data from patients with ASA class I and II.50 Remimazolam could reduce the incidence of postoperative nausea and vomiting in the patients after laparoscopic gynaecological surgery under general anaesthesia as compared with desflurane (…”
BackgroundResultInfluentialWiltshire, H. R., Kilpatrick, G. J., Tilbrook, G. S., & Borkett, K. M. (2012) · Anesthesia & Analgesia · doi:10.1213/ane.0b013e318241f68a · Cited by 215 · cited 4×
“3 mg/kg remimazolam, the maximum effect of sedation was achieved within 3 min of injection.(17,22) Part I of this study discovered that remimazolam had an approximately three times greater systemic clearance (CL) than midazolam {0.”
BackgroundInfluentialKeam, S. J. (2020) · Drugs · doi:10.1007/s40265-020-01299-8 · Cited by 188
Liu, T., Lai, T., Chen, J., Lu, Y., He, F., Chen, Y., & Xie, Y. (2021) · Pharmacology Research & Perspectives · doi:10.1002/prp2.851 · Cited by 146 · cited 1×
“pharmacologically inactive, it does not affect liver and kidney function and can be safely used among patients with impaired liver or renal function.(28,29) No significant differences were observed in the pharmacokinetics of remimazolam between healthy individuals and patients with end-stage renal disease.”
BackgroundRemimazolam besilate, a benzodiazepine, has been approved for general anesthesia!!
Masui, K. (2020) · Journal of Anesthesia · doi:10.1007/s00540-020-02755-1 · Cited by 123 · cited 2×
“In January 2020, remimazolam besylate was approved for use in the induction and maintenance of general anaesthesia in Japan.48 Several clinical trials were conducted to assess the use of remimazolam for general anaesthesia (Table 5).”
MethodInduction and maintenance of procedural sedation in adults: focus on remimazolam injection
Chen, W., Chen, S., & Huang, Y. (2021) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2021.1901575 · Cited by 25 · cited 3×
“Ideal, fast-onset anaesthetics and sedatives with sedative–hypnotic properties, a high therapeutic ratio of toxic dose to a minimum effective dose, and the least possible risk of sideeffects when meeting sedation requirements is warranted in the anaesthesia and critical care domains.(1,8,9) Remimazolam (CNS7056) is a…”
Background
Metadata
- Authors
- Hu, Q., Liu, X., Wen, C., Li, D., & Lei, X.
- Venue
- Drug Design, Development and Therapy
- Publisher
- Informa UK Limited
- Published
- 2022-11
- Volume
- Volume 16
- Pages
- 3957-3974
- ISSN
- 1177-8881 (ISSN-L)
- OpenAlex
- W4308991647
- Cited by
- 211
- References
- 10
- FWCI
- 40.85
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Remimazolam: An Updated Review of a New Sedative and Anaesthetic. https://app.cochat.ai/papers/10.2147/dddt.s384155
- The paper
- Hu, Q., Liu, X., Wen, C., Li, D., & Lei, X. (2022). Remimazolam: An Updated Review of a New Sedative and Anaesthetic. Drug Design, Development and Therapy. https://doi.org/10.2147/dddt.s384155
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.